Skip to main content
HCPCS Q5168 · Level II · Part B drug

Q5168: ranibizumab-leyk (Nufymco), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5168

Billing unit
0.1 MG
Inj. nufymco, 0.1 mg
ASP payment limit
$26.384
October 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI K
APC 0975
NCCI exposure
no PTP pairs
Coverage articles
1
5 states

TL;DR

HCPCS Q5168 is the Level II code for Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg, billed per 0.1 MG. The Medicare Part B ASP payment limit for October 2026 is $26.384 per billing unit. Under OPPS it carries status indicator K in APC 0975. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names ranibizumab: Q5128 (biosimilar ranibizumab-eqrn (Cimerli) from Sandoz Inc); Q5124 (biosimilar ranibizumab-nuna (Byooviz)); J2779 (non-biosimilar ranibizumab (Susvimo) from Genentech, Inc.; implant and intravitreal route); J2778 (non-biosimilar ranibizumab from Genentech, Inc.; billed per 0.1 mg). The ASP crosswalk maps 1 NDC to it, sold as Nufymco by Zydus Pharmaceuticals (USA) Inc. 1 Medicare coverage article lists the code across 5 states, including A52451.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5168 at $26.384 per 0.1 MG for October 2026, derived from manufacturer average sales price plus 6%. Beneficiary coinsurance is 20%.

ASP payment limits for Q5168
QuarterPayment limitPerCoinsurance
October 2026$26.3840.1 MG20%
July 2026n/a0.1 MG—
CMS note: Added October 2026

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to Q5168. Report the NDC in the claim's drug segment and bill the number of Q5168 units that equals the quantity administered divided by 0.1 MG; the last column gives units per full package.

NDCs that crosswalk to Q5168
NDCDrug nameLabelerPackage sizeBilling units / package
70710-2173-01NufymcoZydus Pharmaceuticals (USA) Inc.0.05 × 15

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for Q5168 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for Q5168 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5168 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5168 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5168 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists Q5168 in their HCPCS tables, covering 5 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q5168
ArticleTitleContractor(s)StatesRelated LCD
A52451Billing and Coding: Ranibizumab, Aflibercept and biosimilarsWellpoint FederalCT IL MN NY WIL33394

Diagnoses Medicare contractors cover for Q5168

One billing and coding article attaches a covered diagnosis list to Q5168: 230 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q5168
ICD-10-CMDescription (FY2027)Articles covering
E08.311Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema1 of 1
E08.319Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema1 of 1
E08.3211Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye1 of 1
E08.3212Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye1 of 1
E08.3213Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral1 of 1
E08.3291Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye1 of 1
E08.3292Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye1 of 1
E08.3293Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral1 of 1
E08.3311Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye1 of 1
E08.3312Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye1 of 1
E08.3313Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral1 of 1
E08.3391Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye1 of 1
E08.3392Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye1 of 1
E08.3393Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral1 of 1
E08.3411Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye1 of 1
215 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5168 are counted here: a group whose instructions name Q5168, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q5168, by article
ArticleContractorGroups that applyCovered codes for Q5168Full list
A52451Wellpoint Federalgroup 1 applies to Q5168230On LCD L33394

Local coverage policies that list Q5168

1 active Local Coverage Determination lists Q5168 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5168 carries status indicator K and is assigned to APC 0975, with a published national unadjusted payment of $26.38. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5168 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $26.38 per 0.1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5168 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5168

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5168

What does HCPCS code Q5168 describe?

Q5168 is defined by CMS as "Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg". Each billing unit represents 0.1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5168 a CPT code?

No. Q5168 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as ranibizumab-leyk (Nufymco); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5168 reports the drug itself in 0.1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5168 in October 2026?

The ASP-based payment limit is $26.384 per 0.1 MG, with 20% beneficiary coinsurance. Commercial payers use their own fee schedules.

Which NDCs map to Q5168?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Nufymco (Zydus Pharmaceuticals (USA) Inc.). For example NDC 70710-2173-01 (package size 0.05) equals 5 billing units of Q5168.

Does Q5168 have NCCI bundling edits?

No active practitioner PTP pairs list Q5168 as a column-1 or column-2 code in the v323r0 release.

Q5168 vs Q5128: what is the difference?

Both are HCPCS Level II codes whose descriptor names ranibizumab. What sets Q5128 apart: biosimilar ranibizumab-eqrn (Cimerli) from Sandoz Inc. Q5168 is billed per 0.1 mg, limit $26.384; Q5128 is billed per 0.1 mg, limit $81.13, MUE 10. Report the code whose descriptor matches the product and setting in the record.

Q5168 vs Q5124: what is the difference?

Both are HCPCS Level II codes whose descriptor names ranibizumab. What sets Q5124 apart: biosimilar ranibizumab-nuna (Byooviz). Q5168 is billed per 0.1 mg, limit $26.384; Q5124 is billed per 0.1 mg, limit $249.493, MUE 10. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention Q5168?

1 current Billing and Coding Article in the Medicare Coverage Database lists Q5168, covering 5 states: A52451 (Billing and Coding: Ranibizumab, Aflibercept and biosimilars).

What diagnosis codes support Q5168?

One Medicare billing and coding article lists 230 covered ICD-10-CM codes for Q5168, for example E08.311 (Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema); E08.319 (Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema); E08.3211 (Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye); E08.3212 (Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye); E08.3213 (Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.